期刊
ENDOCRINE REVIEWS
卷 40, 期 5, 页码 1207-1249出版社
ENDOCRINE SOC
DOI: 10.1210/er.2018-00222
关键词
-
资金
- National Natural Science Foundation of China [81822034, 81773119, 81402396]
- National Key Research and Development Program of China [2017YFA0106800, 2018YFA0109200]
- West China Second Hospital, Sichuan University [KS021]
- Robert A. Welch Foundation [E-0004]
- Swedish Cancer Foundation
- Center for Innovative Medicine
- Novo Nordisk Fund
Nuclear receptors (NRs) are transcription factors actively involved in many aspects of human physiology and pathology, serving as sensors of stimuli, master regulators of downstream molecular events, and hubs governing complex gene regulatory networks. The importance of various members of the NR superfamily in cancer has led to substantial efforts to target them therapeutically. Notably, drugs that block the action of estrogen receptor (ER)alpha in patients with ER alpha(+) breast cancer or the androgen receptor (AR) in patients with prostate cancer have provided remarkable improvements in survival. However, there is continuing need for novel drugs that target ER alpha or the AR owing to resistance to established drugs, and there are also promising opportunities for targeting other NRs in cancer. In this review, we provide an overview of NR-based drug discovery in cancer and related resistance mechanisms, focusing on novel strategies for targeting well-established NR targets, including ER alpha, the AR, the glucocorticoid receptor, and the progesterone receptor, as well as opportunities to target other NRs that are attracting interest in immuno-oncology, such as liver X receptors, retinoic acid-related orphan receptors, and farnesoid X receptors.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据